Patents by Inventor James Andya

James Andya has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODY FORMULATIONS
    Publication number: 20230263895
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: June 21, 2022
    Publication date: August 24, 2023
    Applicant: Genentech, Inc.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • ANTI-OX40 ANTIBODIES AND METHODS OF USE
    Publication number: 20210009705
    Abstract: The invention provides anti-OX40 antibodies and methods of using the same.
    Type: Application
    Filed: June 24, 2020
    Publication date: January 14, 2021
    Applicant: Genentech, Inc.
    Inventors: Changchun DU, Jeong KIM, Jing ZHU, Jack BEVERS, III, Kevin WALSH, Patricia DE ALMEIDA, James ANDYA, Ye SHEN
  • Anti-OX40 antibodies and methods of use
    Patent number: 10730951
    Abstract: The invention provides anti-OX40 antibodies and methods of using the same.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventors: Changchun Du, Jeong Kim, Jing Zhu, Jack Bevers, III, Kevin Walsh, Patricia De Almeida, James Andya, Ye Shen
  • ANTIBODY FORMULATIONS
    Publication number: 20200179515
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: February 7, 2020
    Publication date: June 11, 2020
    Applicant: Genentech, Inc.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS
    Publication number: 20190062444
    Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering an anti-angiogenesis agent and an OX40 binding agonist.
    Type: Application
    Filed: June 28, 2018
    Publication date: February 28, 2019
    Applicant: Genentech, Inc.
    Inventors: Kevin Walsh, Patricia De Almeida, Changchun Du, Jeong Kim, Jing Zhu, Jack Bevers, III, James Andya, Ye Shen
  • ANTI-OX40 ANTIBODIES AND METHODS OF USE
    Publication number: 20180230227
    Abstract: The invention provides anti-OX40 antibodies and methods of using the same.
    Type: Application
    Filed: April 11, 2018
    Publication date: August 16, 2018
    Applicant: Genentech, Inc.
    Inventors: Changchun DU, Jeong KIM, Jing ZHU, Jack BEVERS, III, Kevin WALSH, Patricia DE ALMEIDA, James ANDYA, Ye SHEN
  • ANTIBODY FORMULATIONS
    Publication number: 20180221488
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: March 26, 2018
    Publication date: August 9, 2018
    Applicant: Genentech, Inc.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • Anti-OX40 antibodies and methods of use
    Patent number: 9975957
    Abstract: The invention provides anti-OX40 antibodies and methods of using the same.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: May 22, 2018
    Assignee: Genentech, Inc.
    Inventors: Changchun Du, Jeong Kim, Jing Zhu, Jack Bevers, III, Kevin Walsh, Patricia De Almeida, James Andya, Ye Shen
  • COMBINATION THERAPY COMPRISING ANTI-ANGIOGENESIS AGENTS AND OX40 BINDING AGONISTS
    Publication number: 20170015755
    Abstract: The invention provides compositions and methods for treating cancers. The method comprises administering an anti-angiogenesis agent and an OX40 binding agonist.
    Type: Application
    Filed: September 29, 2016
    Publication date: January 19, 2017
    Applicant: Genentech, Inc.
    Inventors: Kevin WALSH, Patricia DE ALMEIDA, Changchun DU, Jeong KIM, Jing ZHU, Jack BEVERS, III, James ANDYA, Ye SHEN
  • Protein formulation
    Patent number: 9283273
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: March 15, 2016
    Assignee: GENENTECH, INC.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Treating a mammal with a formulation comprising an antibody which binds IgE
    Patent number: 9180189
    Abstract: A method of treating a mammal with a formulation comprising an antibody which binds IgE as described.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: November 10, 2015
    Assignee: GENENTECH, INC.
    Inventors: James Andya, Chung C. Hsu, Steven J. Shire, Sylvia Sau-Yan Wu
  • ANTI-OX40 ANTIBODIES AND METHODS OF USE
    Publication number: 20150307617
    Abstract: The invention provides anti-OX40 antibodies and methods of using the same.
    Type: Application
    Filed: March 30, 2015
    Publication date: October 29, 2015
    Applicant: Genentech, Inc.
    Inventors: Changchun DU, Jeong Kim, Jing Zhu, Jack Bevers, III, Kevin Walsh, Patricia De Almeida, James Andya, Ye Shen
  • ANTIBODY FORMULATIONS
    Publication number: 20150196642
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: March 30, 2015
    Publication date: July 16, 2015
    Applicant: GENENTECH, INC.
    Inventors: JAMES ANDYA, SHIANG C. GWEE, JUN LIU, YE SHEN
  • Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody
    Patent number: 9017671
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Grant
    Filed: October 25, 2012
    Date of Patent: April 28, 2015
    Assignee: Genentech, Inc.
    Inventors: James Andya, Shiang C. Gwee, Jun Liu, Ye Shen
  • PROTEIN FORMULATION
    Publication number: 20130224185
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Application
    Filed: September 14, 2012
    Publication date: August 29, 2013
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Antibody formulations
    Patent number: 8372396
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Grant
    Filed: September 4, 2009
    Date of Patent: February 12, 2013
    Assignee: Genetech, Inc.
    Inventors: James Andya, Shiang C. Gwee, Jun Liu, Ye Shen
  • Protein Formulation
    Publication number: 20110236383
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Application
    Filed: June 8, 2011
    Publication date: September 29, 2011
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • PROTEIN FORMULATION
    Publication number: 20100158899
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Application
    Filed: February 2, 2010
    Publication date: June 24, 2010
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • Protein formulation
    Patent number: 7682609
    Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.
    Type: Grant
    Filed: May 26, 2006
    Date of Patent: March 23, 2010
    Assignee: Genentech, Inc.
    Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
  • ANTIBODY FORMULATIONS
    Publication number: 20100015157
    Abstract: The present application describes antibody formulations, including monoclonal antibodies formulated in histidine-acetate buffer, as well as a formulation comprising an antibody that binds to domain II of HER2 (for example, Pertuzumab), and a formulation comprising an antibody that binds to DR5 (for example, Apomab).
    Type: Application
    Filed: September 4, 2009
    Publication date: January 21, 2010
    Applicant: Genentech, Inc.
    Inventors: James Andya, Shiang C. Gwee, Jun Liu, Ye Shen